In 2009, the American Society of Clinical Oncology annual meeting reported that trastuzumab combined with chemotherapy can significantly improve the OS of HER2-positive patients with advanced GC, which was a landmark in GC precision therapy [22]. The gene discussed is ERBB2; the disease is gastric cancer.